Effects of preoperative paclitaxel combined with nedaplatin chemotherapy on the amount of bleeding and postoperative radical resection in patients with locally advanced esophageal carcinoma undergoing esophagectomy
Huang Xiaoyu, Geng Mingfei, Cao Jianwei, Zhu Dongshan
Published 2017-10-25
Cite as Chin J Pract Med, 2017,44(20): 62-65. DOI: 10.3760/cma.j.issn.1674-4756.2017.20.021
Abstract
ObjectiveTo investigate the effects of preoperative paclitaxel combined with nedaplatin chemotherapy on the amount of bleeding and postoperative radical resection in patients with locally advanced esophageal carcinoma undergoing esophagectomy.
MethodsSixty-two patients with locally advanced esophageal cancer were randomly divided into control group and study group, with 31 cases in each group. The study group was given paclitaxel combined with nedaplatin chemotherapy and esophagectomy, and the control group was only given esophagectomy. At admission and 1 month after treatment, the incidence of complications were compared between the two groups. The patients were followed-up, life quality scores from 6 months to 24 months after operation, and the survival rates were compared.
ResultsThere was no significant difference in the surgical time or hospitalization time between the study group and the control group (P>0.05), but the postoperative bleeding volume and radical resection rate of the study group were significantly higher than those of the control group (P<0.05); Before treatment, there was no significant difference in the social function, emotional function, overall symptoms or physical function scores between the study group and the control group (P>0.05), but after 1 month of treatment, each score of the two groups was significantly higher than those before treatment, and those of the study group were significantly higher than those of the control group (P<0.05). There was no significant difference in the incidence of complications between the study group [19.36% (6/31)] and the control group [25.82% (8/31)] (P>0.05). There was no significant difference in the survival rate at 6 months, 12 months and 18 months after treatment between the study group and the control group (P>0.05), but the survival rate at 24 months after treatment of the study group [77.42% (24/31)] was higher than that of the control group [51.61% (16/31)], the difference was significant (P<0.05).
ConclusionsPaclitaxel combined with nedaplatin chemotherapy before esophagectomy can effectively reduce the intraoperative blood loss of patients with locally advanced esophageal cancer, and improve the radical resection rate, survival rate, improve the quality of life and has high safety.
Key words:
Paclitaxel; Nedaplatin; Locally advanced esophageal carcinoma; Esophagectomy; Radical resection rate
Contributor Information
Huang Xiaoyu
Department of Thoracic Surgery, Anyang Cancer Hospital, Anyang 455000, China
Geng Mingfei
Cao Jianwei
Zhu Dongshan
